Eclerx Services Buyback 2025 vs Nectar Lifesciences Buyback 2025

Comparison between Eclerx Services Buyback 2025 and Nectar Lifesciences Buyback 2025.

Buyback Details

Eclerx Services Buyback 2025 is a Tender Offer buyback proposed to list at BSE, NSE while Nectar Lifesciences Buyback 2025 is a Tender Offer proposed to list at BSE, NSE.

 Eclerx Services Ltd.Nectar Lifesciences Ltd.
LogoEclerx Services Buyback 2025 LogoNectar Lifesciences Buyback 2025 Logo
Type of BuybackTender OfferTender Offer
Listing AtBSE, NSEBSE, NSE
Face Value₹10 per share₹1 per share
Buyback Price₹4800 per share₹27 per share
Issue Size6,25,000 shares3,00,00,000 shares
Issue Size (Amount)₹300.00 Crores₹81.00 Crores
Buyback Ratio
CategoryEntitlement Ratio of BuybackShares Offered
Reserved Category for Small Shareholders3 Equity Shares out of every 19 Fully paid-up Equity Shares held on the Record Date.93,750
General Category for all other Eligible Shareholders3 Equity Shares out of every 121 Fully paid-up Equity Shares held on the Record Date.5,31,250
CategoryEntitlement Ratio of BuybackShares Offered
Reserved Category for Small Shareholders25 Equity Shares out of every 103 Fully paid-up Equity Shares held on the Record Date.1,32,51,651
General Category for all other Eligible Shareholders25 Equity Shares out of every 103 Fully paid-up Equity Shares held on the Record Date.1,67,48,349
RegistrarKfin Technologies Ltd.Kfin Technologies Ltd.
Lead ManagersEmkay Global Financial Services Ltd.Master Capital Services Ltd.
Necessity of the buyback

The Company is proposing the Buy Back to return surplus funds to the Eligible Shareholders, which are over and above its ordinary capital requirements and in excess of any current investment plans, in an expedient, efficient and cost-effective manner. The Buy Back would increase the shareholders' value and would also help the company in fulfilling the following objectives:

  1. The Buy Back will help the Company to return surplus cash to its shareholders holding Equity Shares broadly in proportion to their shareholding, thereby enhancing the overall return to the shareholders:
  2. The Buy Back, which is being implemented through the 'Tender Offer' as prescribed under the SEBI Buy Back Regulations, would involve allocation of 15% of the number of Equity Shares which the Company proposes to Buy Back or the number of Equity Shares entitled as per the shareholding of Small Shareholders, whichever is higher, to Small Shareholders. The Company believes that this reservation of 15% for Small Shareholders would benefit a large number of public shareholders, who would get classified as "Small Shareholders":
  3. The Buy Back may improve return on equity by reducing the equity base, thereby increasing shareholders' value in the long term.
  4. The Buy Back will help in achieving an optimal capital structure.
  5. The Buy Back gives an option to the shareholders holding Equity Shares of the Company, to either (i) choose to participate and get cash instead of Equity Shares to be accepted under the Buy Back Offer or (ii) choose not to participate and enjoy a resultant increase in their percentage shareholding, post the Buy Back Offer, without additional investment.
  • The buyback will help the company to return surplus cash to its shareholders holding equity shares broadly in proportion to their shareholding, thereby, enhancing the overall return to shareholders.
  • The buyback will help the company to optimize the capital structure;
  • The Buyback, which is being implemented through the Tender Offer route as prescribed under the SEBI Buyback Regulations, would involve allocation of the number of equity shares as per their entitlement or 15% of the number of equity shares to be bought back, whichever is higher, reserved. The company believes that the reservation for small shareholders would benefit a large number of the Company's public shareholders, who get classified as "Small Shareholders, as per regulations 2(i)(n) of the SEBI Buyback Regulations.
  • The buyback may help in improving financial ratios like earnings per share, return on capital employed, and return on equity, by reduction in the equity base, thereby leading to long-term increase in shareholders' vlaue; and
  • The buyback gives an option to the shareholders holding Equity shares of the company, who can choose to participate and get cash in lieu of Equity shares to be accepted under the Buyback offer or they may choose not to participate and enjoy a resultant increase in their percentage shareholding, post the buyback offer, without additional investment.

Buyback Timetable

Eclerx Services Buyback 2025 and Nectar Lifesciences Buyback 2025 buyback timetable. The investors should have the company's shares in their demat accounts as of the record date. Eclerx Services Buyback 2025 Buyback record date is Dec 17, 2025. Nectar Lifesciences Buyback 2025 Buyback record date is Dec 24, 2025.

 Eclerx Services Ltd.Nectar Lifesciences Ltd.
Record DateDec 17, 2025Dec 24, 2025
Offer Open DateDec 22, 2025Dec 31, 2025
Offer Closure DateDec 29, 2025Jan 06, 2026
Last date for receipt of tender formsDec 29, 2025Jan 06, 2026
Finalisation of buybackJan 01, 2026Jan 12, 2026
Last Date for settlment of bidsJan 02, 2026Jan 13, 2026
Last Date for extinguishment of sharesJan 13, 2026Jan 22, 2026

Financial Details and Other Relevent Information

Comparison of Eclerx Services Buyback 2025 and Nectar Lifesciences Buyback 2025 financial data. The table below also includes a list of all relevant information like Stock Market Data, Compay Information, Lead Manager and Registrar.

 Eclerx Services Ltd.Nectar Lifesciences Ltd.
Financial

Eclerx Services Limited Financial (Restated Consolidated)

Eclerx Services Limited's revenue increased by 15% and profit after tax (PAT) rose by 6% between the financial year ending with March 31, 2025 and March 31, 2024.

Period Ended30 Sep 202531 Mar 202531 Mar 202431 Mar 2023
Total Income1,980.763,452.392,991.182,713.85
Profit After Tax325.01541.26511.73489.18
NET Worth2,626.782,307.962,249.471,716.55
Reserves and Surplus2,577.242,258.802,199.271,668.52
Total Borrowing0.99
Amount in ₹ Crore

Company Financials (Restated Consolidated)

Nectar Lifesciences Ltd.'s revenue decreased by 1% and profit after tax (PAT) dropped by 2376% between the financial year ending with March 31, 2025 and March 31, 2024.

Period Ended30 Sep 202531 Mar 202531 Mar 202431 Mar 2023
Total Income11.301,674.971,698.661,566.85
Profit After Tax-1.01-113.684.99-24.18
NET Worth716.87956.111,069.251,064.59
Reserves and Surplus694.44933.681,046.821,042.17
Total Borrowing458.85582.02635.54753.83
Amount in ₹ Crore
Stock price at BSE

Stock price at BSE (in preceding 3 months)

Month High Price Low Price Average Price
Nov-2025 4861.95 4040.95 4485.47
Oct-2025 4826.00 3907.00 4267.32
Sep-2025 4600.00 3981.25 4320.58

Stock price at BSE (in preceding 3 months)

Month High Price Low Price Average Price
Nov-2025 16.99 13.75 14.67
Oct-2025 16.01 13.31 14.26
Sep-2025 17.03 14.07 15.15
Stock price at NSE

Stock price at NSE (in preceding 3 months)

Month High Price Low Price Average Price
Nov-2025 4867.90 4252.00 4488.06
Oct-2025 4830.00 3906.00 4267.84
Sep-2025 4600.00 3982.80 4320.77

Stock price at NSE (in preceding 3 months)

Month High Price Low Price Average Price
Nov-2025 16.99 13.71 14.64
Oct-2025 15.76 13.10 14.18
Sep-2025 16.99 14.03 15.12

Compare with others

Compare:

Eclerx Services Buyback 2025 and Nectar Lifesciences Buyback 2025